BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37796174)

  • 1. 68 Ga-PSMA PET/CT in Hepatic Metastasis From Pancreatic Neuroendocrine Tumor.
    Chen S; Lin Z; Wang C; Miao W
    Clin Nucl Med; 2023 Nov; 48(11):991-993. PubMed ID: 37796174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.
    Zahed H; Beauregard JM; Abikhzer G; Rush C; Probst S
    Clin Nucl Med; 2023 Jan; 48(1):e12-e15. PubMed ID: 36240803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
    Acar E; Kaya GÇ
    Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Prognostic Value of PET/CT Imaging with Combination of
    Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
    Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
    Chan M; Schembri GP
    Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective head-to-head comparison of
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of Extramedullary Plasmacytomas Involving Lymph Nodes and Pancreas Revealed by 68Ga-DOTATATE and 18F-FDG PET/CT.
    Pan Q; Luo Y; Li J; Zhang S; Li F
    Clin Nucl Med; 2018 Dec; 43(12):936-938. PubMed ID: 30179917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of
    Liu Q; Zang J; Yang Y; Ling Q; Wu H; Wang P; Lu L; Zhu Z
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4386-4395. PubMed ID: 34146130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.
    Ulaner GA; Bodei L
    Clin Nucl Med; 2019 Apr; 44(4):330-331. PubMed ID: 30688738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT and 68Ga-DOTATOC PET/CT in Diffuse Pancreatic Neuroendocrine Tumor.
    Ji X; Dong A; He Q; Dong H; Zuo C
    Clin Nucl Med; 2020 May; 45(5):e245-e248. PubMed ID: 32049733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solitary Pulmonary Perivascular Epithelial Cell Tumor Mimicking Pulmonary Metastasis on 68 Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
    Liang S; Chen X
    Clin Nucl Med; 2024 Jun; 49(6):567-568. PubMed ID: 38631001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-Specific Membrane Antigen (PSMA) Avid Pancreatic Neuroendocrine Tumor.
    Vamadevan S; Shetty D; Le K; Bui C; Mansberg R; Loh H
    Clin Nucl Med; 2016 Oct; 41(10):804-6. PubMed ID: 27454602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Quantification of
    Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA
    Acad Radiol; 2022 Sep; 29(9):1308-1316. PubMed ID: 34836776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.